Glanbia PLC: 1Q26 Beat & Raise — Volume-Driven Upside with Upgraded Guidance

Core Conclusion

Glanbia’s 1Q26 like-for-like (LFL) growth of +7.2% beat Bloomberg consensus of +4.2% and accelerated from 4Q25’s +6.9%, driven by a volume-led outperformance in Performance Nutrition (PN) and Health & Nutrition (H&N). Management raised FY26 group adjusted EPS growth guidance to the upper end of the prior +7–11% range (constant FX), implying a ~2ppt upgrade. The stock trades at 15x CY26E P/E, a 12% discount to EU Staples. The beat is largely volume-driven, but key questions remain on sustainability of international momentum and capacity constraints.

What the Market May Be Underestimating

The upgrade was driven primarily by stronger-than-expected volumes in PN International (+23.4% LFL) and H&N (+11.6% LFL), not by Dairy Nutrition (DN) despite its EBITDA guidance increase. DN EBITDA upgrade alone contributes only ~1–2% to group EPS, meaning the bulk of the earnings revision comes from the nutrition divisions. Markets may be underappreciating the volume-led nature of this beat and the potential for further upward revision if international momentum persists. However, the Americas PN portfolio ex-ON declined ~14% LFL, indicating concentration risk.

Evidence Chain

• 1Q26 LFL +7.2% (consensus +4.2%, 4Q25 +6.9%). Volume +8.2% (vs. consensus +3.5%), price -1.0% (consensus +0.8%).
• PN: LFL +11.5% (consensus +7.2%, 4Q25 ex SlimFast +10.5%). Volume +9.2% (+3.9% consensus), price +2.3%. International +23.4% LFL, Americas +4.0%. Core brand Optimum Nutrition (ON) +18.8% LFL (4Q +12.3%).
• H&N: LFL +11.6% (consensus +4.9%, 4Q25 +8.8%). Volume +12.5% (consensus +5.4%), price -0.9% (pass-through pricing). Driven by EMEA and ASPAC momentum.
• DN: LFL +2.0% (consensus +3.0%, 4Q25 +4.8%). Volume +6.4% (consensus +2.9%), price -4.4% (negative cheese markets, partly offset by whey protein pricing).
• Guidance: FY26 PN LFL now expected at upper end of +5–7% (prior +5–7%), H&N upper end of +4–6% (prior +4–6%). Group Adj EPS at upper end of +7–11% cFX (prior +7–11%). DN EBITDA raised to $160–170m (prior ~$150–160m, consensus $157m).
• Buyback: €22.2m returned out of €100m FY26 authority as of April 27.

Key Risks and Disagreements

• Sustainability of PN International growth: +23.4% LFL was boosted by easy comps and new distribution. Capacity constraints in whey protein concentrate (WPC) offtake and production may limit further acceleration. The company previously flagged flat PN volumes for FY26; current guidance implies +LSD volume growth, which may prove conservative if international demand holds.
• Americans PN weakness: Other portfolio brands (ex-ON and Isopure) saw ~14% LFL decline. Continued deterioration could offset ON momentum.
• Middle East exposure: Group estimates the region contributes low-single-digit % of PN revenue. Guidance upgrade suggests limited near-term impact, but conflict escalation remains a tail risk.
• Input cost inflation and pricing: Negative pricing across H&N and DN (pass-through) may pressure margins if commodity costs rise. PN pricing positive but moderating.

Valuation and Trading Implications

At 15x CY26E P/E, a 12% discount to EU Staples (vs. 30% 10-year average discount), the stock is not expensive but also not cheap given the narrow earnings beat. The upgrade is modest (+2ppt to EPS growth), and the risk of volume normalization in H2 exists. DCF-based price target of €18.7 (WACC 9%, terminal growth 2%) and P/E-based target of $17.4 (14x NTM P/E) imply ~7% upside from €17.52 close. For investors with a longer horizon, the narrowed discount and volume-led inflection support a constructive view, but near-term catalysts are limited after the raise. Key swing factors: continued International volume momentum, Americas portfolio stabilization, and capacity investments.

Appendix Data Summary (Key Metrics)

Note: Consensus from Bloomberg for 1Q26; Visible Alpha for other periods.